To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

• ClinicalTrials.gov Identifier: NCT00258050
• Recruitment Status: Completed
• First Posted: November 24, 2005
• Last Update Posted: December 6, 2017
• Sponsor: GlaxoSmithKline
• Information provided by (Responsible Party): GlaxoSmithKline

Tracking Information

• First Submitted Date: November 22, 2005
• First Posted Date: November 24, 2005
• Last Update Posted Date: December 6, 2017
• Actual Study Start Date: November 21, 2005
• Actual Primary Completion Date: February 8, 2007 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 4, 2017)

• Area under the concentration versus time curve (AUC) of midazolam [ Time Frame: Pre-dose, 2 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose on Day 1, Day 3, Day 9 and Day 11 ]
  Blood samples will be collected at indicated time points for the determination of midazolam concentration. AUC of midazolam in the presence and absence of lapatinib will be determined.
• Maximum observed concentration (Cmax) of midazolam [ Time Frame: Pre-dose, 2 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose on Day 1, Day 3, Day 9 and Day 11 ]
  Blood samples will be collected at indicated time points for the determination of midazolam concentration. Cmax of midazolam in the presence and absence of lapatinib will be determined.
• Clearance (CL) of midazolam [ Time Frame: Pre-dose, 2 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose on Day 1, Day 3, Day 9 and Day 11 ]
  Blood samples will be collected at indicated time points for the determination of midazolam concentration. CL of midazolam in the presence and absence of lapatinib will be determined.
• Half-life (t½) of midazolam [ Time Frame: Pre-dose, 2 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose on Day 1, Day 3, Day 9 and Day 11 ]
  Blood samples will be collected at indicated time points for the determination of midazolam concentration. t1/2 of midazolam in the presence and absence of lapatinib will be determined.
• Absolute bioavailability (F) of midazolam [ Time Frame: Pre-dose, 2 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose on Day 1, Day 3, Day 9 and Day 11 ]
  Blood samples will be collected at indicated time points for the determination of midazolam concentration. Absolute bioavailability of midazolam in the presence and absence of lapatinib will be determined.

• Original Primary Outcome Measures (submitted: November 23, 2005): To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients.

Current Secondary Outcome Measures (submitted: December 4, 2017)

• Time of maximum observed concentration (tmax) of midazolam [ Time Frame: Pre-dose, 2 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose on Day 1, Day 3, Day 9 and Day 11 ]
  Blood samples will be collected at indicated time points for the determination of midazolam concentration.
• Volume of distribution (Vss) of midazolam [ Time Frame: Pre-dose, 2 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-dose on Day 1, Day 3, Day 9 and Day 11 ]
  Blood samples will be collected at indicated time points for the determination of midazolam concentration.
• Number of subjects with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Up to Month 7 ]
  An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events may require medical or surgical intervention to prevent one of the other outcomes listed above.
• Number of subjects with abnormal clinical chemistry parameters [ Time Frame: Up to Month 7 ]
  The following clinical chemistry parameters were evaluated: sodium, potassium, total carbon dioxide (CO2), calcium, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and blood urea nitrogen (BUN).
• Number of subjects with abnormal hematology parameters [ Time Frame: Up to Month 7 ]
  The following hematology parameters were evaluated: hemoglobin, hematocrit, red blood cell count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, eosinophil count and basophil count.
• Number of subjects with abnormal blood pressure [ Time Frame: Up to Month 7 ]
  Systolic and diastolic blood pressure will be measured.
• Number of subjects with abnormal heart rate [ Time Frame: Up to Month 7 ]
  Heart rate will be measured.

• Original Secondary Outcome Measures (submitted: November 23, 2005): To assess the safety and tolerability of chronic oral lapatinib therapy in cancer patients.
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
• Official Title: A Four-Way Cross-Over Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally and Intravenously Administered Midazolam in Cancer Patients
• Brief Summary: To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients. Also to assess the safety and tolerability of chronic oral lapatinib therapy in cancer patients.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Neoplasms, Breast

Intervention

• Drug: Midazolam
  Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
  Other Name: GW572016 oral tablets
• Drug: Lapatinib
  Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.

Study Arms

Experimental: Subjects with cancer

In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.

In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study.

Interventions:

• Drug: Midazolam
• Drug: Lapatinib

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 4, 2017): 24
• Original Enrollment (submitted: November 23, 2005): 16
• Actual Study Completion Date: February 8, 2007
• Actual Primary Completion Date: February 8, 2007 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion criteria:

• Histologically confirmed, solid tumor refractory to standard therapy.
• Tumor for which there is no standard therapy.
• Able to swallow and retain oral medication.
• ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2.
• Provided written informed consent.
• Adequate bone marrow function.
• Serum creatinine is less than or equal to 1.5 mg/dL.
• Calculated creatinine clearance is greater than or equal to 60 ml/min based on Cockcroft and Gault.
• Total bilirubin is greater than or equal to the upper limit of normal of institutional values.
• Aspartate and alanine transaminase is less than or equal to 3 times the upper limit of the institutional values.
• Have a left ventricular ejection fraction (LVEF) greater than or equal to 40% based on electrocardiogram (ECHO) or multiple gated acquisition scan (MUGA).
• Resting oxygen saturations of greater than 90%.

Exclusion criteria:

• Pregnant or lactating female.
• Have malabsorption syndrome, a disease affecting gastrointestinal function.
• Resection of the stomach or small bowel.
• Evidence of symptomatic or uncontrolled brain metastases or leptomeningeal disease.
• Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations.
• Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product.
• Use of anilinoquinazolines, such as gefitinib [Iressa™], erlotinib [Tarceva™].
• Immediate or delayed hypersensitivity reaction to midazolam or any component of the formulation, including benzyl alcohol (cross-sensitivity with other benzodiazepines may exist).
• Has narrow-angle glaucoma which is a contraindication to midazolam use.
• Has received treatment with any investigational drug in the previous 4 weeks.
• Received chemotherapy, immunotherapy, biologic therapy or hormonal therapy within the past 14 days, with the exception of mitomycin C within the past 6 weeks.
• Currently receiving amiodarone or has received amiodarone in the 6 months prior to screening.
• Is taking regular doses of opiates that in the opinion of the investigator would put the patient at risk of clinically significant respiratory compromise when midazolam is administered.
• Physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• Has Class II to IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
• Clinically significant electrocardiogram (ECG) abnormality.
• Clinically assessed to have inadequate venous access for protocol-related blood draws.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 70 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00258050
• Other Study ID Numbers: EGF10015
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: GlaxoSmithKline
• Study Sponsor: GlaxoSmithKline
• Collaborators: Not Provided

Investigators

• Study Director: GSK Clinical Trials; GlaxoSmithKline

• PRS Account: GlaxoSmithKline
• Verification Date: December 2017